Softgel CDMO · Strategic Manufacturing Intelligence

Softgel Manufacturing Begins with Fill–Shell Compatibility.

A softgel is viable only when liquid or semi-solid fill, shell, seal, coating, packaging and shelf-life evidence work as one system. We evaluate that system before promising a production route.

Initiate R&D Due Diligence Explore Global CDMO Evidence

OWN FACILITIES

Gdynia, Poland

Development, scale-up and commercial manufacturing are performed within IOC’s own certified facilities.

SINCE 2009

Dietary-supplement quality record

No confirmed quality complaints for dietary supplements according to IOC internal quality records.

FIT-FOR-PURPOSE

Analytical evidence

Specialized methods are performed by qualified independent laboratories when required by the product evidence plan.

ISO/IEC 27001

Information security

Client IP and confidential documents are governed within the certified information-security framework.

The Velvet Rope

Admission Is Selective by Design.

We reject mandates that cannot support scientific rigor, regulatory discipline, and enterprise execution standards. Selectivity is not branding — it is quality control for everyone already inside the portfolio.

You need a feasibility assessment, not a catalogue quote for a generic capsule.
You are prepared to examine fill chemistry, shell compatibility, coating, packaging and intended-market requirements together.
You accept that the technically responsible recommendation may be a different delivery format when the evidence requires it.
You are prepared to start with a paid, scoped R&D due-diligence decision.

Evidence Protocol

Reproducibility Before Throughput.

Our own production facilities in Poland use product-specific process controls and documented release requirements. Where specialized analytical evidence is required, qualified independent laboratories provide the relevant method and report.

Process Control

Product-specific critical process parameters

Analytical Release

Evidence plan matched to the product

Continuity

Scale-up within IOC production infrastructure

Governance

ISO/IEC 27001 information-security framework

Strategic Outcomes

What You Actually Acquire.

A product-specific formulation and process route defined for the agreed brief.
A documented scale-up pathway that identifies the evidence required before commercial release.
Contracted project-specific deliverables designed to support ownership and continuity; pre-existing Olympia platforms remain governed separately.

Execution Ladder

Four Moves from Scientific Thesis to Industrial Dominance.

Due Diligence Intake

We assess strategic fit, scientific defensibility, and regulatory complexity before admission.

Formulation Architecture

R&D defines dosage form, ingredient system, and quality-critical parameters.

Validation & PPQ

Pilot and qualification runs establish reproducibility with measurable process capability.

Industrial Deployment

Scale campaigns proceed under controlled analytics and transfer-grade documentation.

CONTRACT MANUFACTURING · SOFTGEL TECHNOLOGY · E-E-A-T

SOFTGEL CONTRACT MANUFACTURING — PRODUCT-SPECIFIC TECHNICAL ASSESSMENT.

Olympia Biosciences™ provides a CDMO pathway for softgel programmes, from technical assessment through the appropriate manufacturing scope. The practical route depends on the product, its intended market and the agreed requirements.

Softgel is one possible delivery format. Whether it is appropriate must be assessed for the relevant formulation, dose, stability, packaging and commercial production constraints.

Softgel decisions are evaluated against the product’s technical and quality requirements; no delivery format or process guarantees a clinical, stability or commercial outcome.

The framework below describes factors commonly considered in formulation and process planning; it does not promise a product outcome.

WHAT IS SOFTGEL CAPSULE MANUFACTURING

What is softgel capsule manufacturing?

Softgel capsule manufacturing develops and produces a sealed capsule around a compatible liquid or semi-solid fill. Whether softgel is the right format depends on fill chemistry, dose, active stability, shell compatibility, the intended market, packaging requirements and commercial production constraints. Suitability must be assessed for the specific product rather than assumed from the category name.

Softgel Production Technology Matrix
TECHNOLOGY	DESCRIPTION	CONSUMER BENEFIT	MANUFACTURER BENEFIT
Liposomal Technology	Encapsulating active ingredients within a lipid bilayer.	Increased bioavailability and stability of active ingredients.	Reduced ingredient loss, increasing production efficiency.
Nano-Micellization	Transforming ingredients into microscopic particles.	Improved absorption of active ingredients by the body.	Higher quality and efficacy of finished products.
Emulsification	Creating emulsions that combine fat-soluble and water-soluble ingredients.	Stable and effective supplement formulas.	The ability to create more complex products.
Supercritical CO₂ Extraction	Sourcing natural oils without chemical solvents.	Cleaner, higher-quality end products.	Increased purity and quality of the process.
Microencapsulation	Surrounding active ingredients with microscopic particles.	Controlled release of ingredients.	Improved stability and production yield.
Sustainable & Eco-Friendly Technologies	Using raw materials from ecological sources.	Minimized environmental impact.	Building a positive brand reputation.
Low-Temperature Mixing & Emulsification	Combining ingredients at lower temperatures.	Preservation of biological properties.	Optimization of production processes.

SCROLL HORIZONTALLY TO REVIEW FULL TECHNOLOGY MATRIX

Final Gate

Initiate R&D Due Diligence.

If your programme requires a defensible decision on format, stability and scale-up, we should assess fit before production is quoted.

Initiate R&D Due Diligence Audit Scale-Up Architecture

Evidence-led format selection | owned production infrastructure | qualified analytical evidence

Frequently Asked Questions

What determines whether a softgel is technically appropriate?

The decision depends on the liquid or semi-solid fill, shell polymer, seal, any enteric coating, packaging, target shelf life, dose and intended market. A category name or an initial quote cannot establish compatibility.

Why is due diligence paid instead of free?

Because the early work is technical: mapping fill–shell interaction risk, format suitability, evidence needs, process route and regulatory constraints. The purpose is to avoid a weak production decision, not to accelerate a generic quote.

What does a softgel feasibility review include?

It defines the product brief, identifies critical compatibility and stability questions, determines what evidence is required and records whether softgel is the appropriate route before formulation and scale-up are scoped.

Where are softgel programmes developed and manufactured?

IOC operates its own certified production facilities in Poland for development, scale-up and commercial manufacturing. Specialized analytical methods may be performed by qualified independent laboratories when the product evidence plan requires them.

Can a technically unsuitable softgel brief be redirected?

Yes. If the evidence indicates that the proposed shell or format is not appropriate, Olympia will state that early and evaluate a different route rather than force a product into an unsuitable capsule.

Who owns the formula and process documentation?

The ownership and portability of contracted project-specific deliverables are set out in the agreement. Olympia’s pre-existing platforms, reusable methods and third-party elements remain governed separately.

RELATED INTELLIGENCE

Global CDMO PortfolioPublic corporate evidence: owned facilities, current compliance records, leadership and operating principles.EXPLORE ›Production Formats & MOQ ReferenceCompare dosage formats and assess feasibility against the actual product brief.EXPLORE ›Technology PlatformDelivery-system capability, product-specific evidence and scale-up considerations.EXPLORE ›Physician Supplement Brand Contract ManufacturingA CDMO route for clinician-led brands requiring scientific and commercial discipline.EXPLORE ›Production Scale-UpA staged route from formulation decisions to controlled commercial manufacturing.EXPLORE ›Supplement Formula IP & Trade Secret ProtectionISO/IEC 27001 information-security governance for client documents and confidential work.EXPLORE ›

Strictly B2B / Educational R&D Disclaimer

The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.

Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.

Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.